[Lung carcinoma. An unusual case of survival]

Lung cancer incidence is continuously increasing over the world, despite significant advances in both the diagnostic and therapeutic fields. At the diagnosis, more than 2/3 of patients present a locally advanced disease associated with a 5-year survival of less than 35%, or with distant metastases associated with no long-time survival. Chemotherapy with cisplatin remains a well established option in the treatment of lung cancer, as confirmed by recent meta-analyses, and its action seems strengthened by the introduction of new agents (taxans, gemcitabine, vinorelbine, topotecan, and others), that are giving promising results for a better control of this disease.